Dyslipidemias
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Finally, a randomized controlled clinical trial revealed that 4-6 weeks of reduced protein intake (7%-9% of calories) decreased VLDL particle number, increased VLDL-bound APOA5 expression, and lowered plasma TGs, consistent with mechanistic conservation of PR-mediated hypotriglyceridemia in humans with translational potential as a nutraceutical intervention for dyslipidemia.
|
30385734 |
2018 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The APOA5 rs662799 polymorphism is associated with dyslipidemia and the severity of coronary heart disease in Chinese women.
|
27716220 |
2016 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Relationship of the APOA5/A4/C3/A1 gene cluster and APOB gene polymorphisms with dyslipidemia.
|
26345861 |
2015 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The objective of this study was to analyze the interaction of a high fat diet with the APOA2 (rs3813627 and rs5082), APOA5 (rs662799 and rs3135506) and LEPR (rs8179183 and rs1137101) polymorphisms and its relationship with obesity and dyslipidemia in young subjects.
|
26365669 |
2015 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The aim of the study was to determine the allelic and genotypic distribution of the APOA5 -1131T>C polymorphism and to identify the association of the genetic variant and the risk for dyslipidemia.
|
23266809 |
2013 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The APOA5 gene region was sequenced in 1,612 individuals with mixed dyslipidemia in a randomized trial of fenofibric acid alone and in combination with statins.
|
23633496 |
2013 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genetic variants of APOA5 and BTN2A1 may synergistically affect the prevalence of dyslipidemia in East Asian populations and of MetS in Japanese individuals.
|
22576629 |
2012 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Moreover, a significant positive interaction between APOA5 553 G/T+T/T genotypes and fat intake ≥ 25% of total energy for the risk of dyslipidemia was observed.
|
22517333 |
2012 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
None of the combined APOA5-APOE polymorphisms increased risk for dyslipidemia.
|
21132386 |
2011 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
|
21889769 |
2011 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
LHGDN |
These results indicate that the association of APOA5 -1131T>C polymorphism with dyslipidemia can also contribute to an increased susceptibility to metabolic syndrome in the Chinese, as a result of its effect on triglyceride metabolism.
|
19055447 |
2008 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These results suggest that in T2D APOA5 polymorphisms contribute to modulate dyslipidemia.
|
18468520 |
2008 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
LHGDN |
These results suggest that in T2D APOA5 polymorphisms contribute to modulate dyslipidemia.
|
18468520 |
2008 |
Dyslipidemias
|
0.100 |
Biomarker
|
group |
LHGDN |
Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia.
|
18658049 |
2008 |
Dyslipidemias
|
0.100 |
Biomarker
|
group |
BEFREE |
Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia.
|
18658049 |
2008 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These results indicate that the association of APOA5 -1131T>C polymorphism with dyslipidemia can also contribute to an increased susceptibility to metabolic syndrome in the Chinese, as a result of its effect on triglyceride metabolism.
|
19055447 |
2008 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
LHGDN |
We evaluated the relationship of the APOA5 -1131T>C and c.56C>G polymorphisms [single nucleotide polymorphism (SNP)] with serum lipids, dyslipidemia [low high-density lipoprotein (HDL)/high triglyceride] and the risk for metabolic syndrome (MS) in the Turkish Adult Risk Factor study.
|
18601598 |
2008 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Excess risk for low HDL-C, dyslipidemia and MS is associated with the rare alleles of the APOA5 SNPs and non-carriers of common haplotype in women.
|
18601598 |
2008 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The contribution to dyslipidemia of 20 selected single nucleotide polymorphisms of 13 genes reported in the literature to be associated with plasma lipid levels (ABCA1, ADRB2, APOA5, APOC3, APOE, CETP, LIPC, LIPG, LPL, MDR1, MTP, SCARB1, and TNF) was assessed by longitudinally modeling more than 4400 plasma lipid determinations in 438 antiretroviral therapy-treated participants during a median period of 4.8 years.
|
17700364 |
2007 |
Dyslipidemias
|
0.100 |
Biomarker
|
group |
BEFREE |
Modifying genes, especially influencing the high triglyceride trait, include APOC3 and APOA5, the latter representing a downstream target of USF1 and implying a USF1-dependent pathway in the molecular pathogenesis of dyslipidemias.
|
16680034 |
2006 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The -1131T-->C polymorphism of the apolipoprotein A-V gene (APO A-V) is tightly linked to lipid metabolism and has been associated with increased triglyceride levels and familial dyslipidemia.
|
16375582 |
2006 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T->C gene variation.
|
16887900 |
2006 |